INTERVIEW: Oraya doesn't see threat from new AMD drugs
This article was originally published in Clinica
Executive Summary
Oraya Therapeutics is ramping up commercialization of its radiotherapy for age-related macular degeneration (AMD), a treatment that could disrupt a market currently dominated by drug giants Novartis and Roche with their anti-VEGF drug Lucentis. Even with the advent of new AMD drugs, such as Regeneron’s approved anti-VEGF therapy Eylea (aflibercept injection) and Ophthotech’s investigational platelet-derived growth factor (PGDF) inhibitor Fovista, Oraya remains unperturbed by its pharma rivals.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.